![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 28, 25883-25888, July 13, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-Catenin Can Occur Independent of CRM1
and the Adenomatous Polyposis Coli Tumor Suppressor*
, and
From the Westmead Institute for Cancer Research, University of
Sydney, Westmead Millennium Institute at Westmead Hospital, New South
Wales 2145, Australia and the
Department of
Biotechnology, Graduate School of Agriculture and Life Science, The
University of Tokyo Yayoi 1-1-1, Bunkyo-ku, Tokyo, 113-8657 Japan
Received for publication, March 26, 2001, and in revised form, May 3, 2001
| |
ABSTRACT |
|---|
|
|
|---|
Recently, APC was identified as a nuclear cytoplasmic shuttling protein
that contains multiple nuclear export signals (17-19) with evidence
supporting the notion that APC can taxi Cell Culture, Antibodies, and Transfections--
SW480 human
colon cancer cells are homozygous for truncated mutant APC (amino acids
1-1337) and were cultured in Dulbecco's modified Eagle's medium with
10% fetal calf serum. Cells were confirmed mycoplasma negative. The
primary antibodies used to detect different cellular proteins are as
follows: Plasmid Construction--
The full-length human Preparation of Cytoplasmic Extract--
Cells were resuspended
in lysis buffer (10 mM Tris-HCL, pH 7.0, 150 mM
KCl, 3 mM MgCl2, 1 mM
CaCl2, 0.2% bovine serum albumin, 3.5% glycerol, 0.5 mM phenylmethylsulfonyl fluoride, and 2 mM dithiothreitol) and lysed on ice following the addition of 0.5% Nonidet P-40. Samples were centrifuged at 1000 rpm for 5 min. The
supernatant was then incubated with 0.5% sodium deoxycholate for 10 min on ice and centrifuged 13,000 rpm for 20 min in a cold room. The
supernatant was collected as the cytosolic fraction and stored at
Permeabilized Cell Export Assay Optimization--
Digitonin was
prepared at a working concentration of 5 mg/ml as described previously
by Gorlich et al. (29). An analysis of SW480 cells
transfected with different GFP fusion constructs that vary in their
capacity for nuclear export (30) showed that doses of 30-50 µg/ml
digitonin effectively disrupted the plasma membrane but not the nuclear
envelope (data not shown). Cells were also assessed by phase
contrast microscopy to ensure morphological integrity of the nuclear
membrane under these conditions.
Export Assay--
The transport assay was performed in principle
as described previously (24, 31) but with several modifications. Cells grown on coverslips in Nunc 8-well trays were first washed 3 times with
PBS and then incubated on ice for 6 min in 0.5 ml of transport buffer
containing 50 mM Tris-HCL, pH 7.5, 5 mM
magnesium acetate, 2 mM EGTA, 50 mM potassium
acetate, 2 mM dithiothreitol, 50 µg/ml phenylmethylsulfonyl fluoride, 1 mM benzamidine, and 50 µg/ml leupeptin in the presence or absence of digitonin (30-50
µg/ml). After permeabilization of the outer membrane, cells were then washed 3 times in PBS and incubated for 30 min in 0.5 ml of transport buffer +/ Immunofluorescence Microscopy and Image Quantification--
For
indirect immunofluorescence analysis, cells (on coverslips) were fixed
in 3% formalin/PBS for 20 min and then permeabilized with 0.2% Triton
X-100/PBS for 10 min. Samples were pre-blocked with 3% bovine serum
albumin/PBS for 30 min, incubated with primary antibodies (diluted 1:80
in blocking solution), and washed in PBS. The cells were then incubated
with secondary antibody (1:120 dilution of a fluorescein
isothiocyanate-conjugated or Texas Red-conjugated anti-rabbit or
anti-mouse antibody from Sigma) and subsequently mounted on slides with
Vectorshield (Vector Laboratories) for fluorescence microscopy. Cells
were processed at room temperature. Cells transfected with GFP or
YFP-fusion constructs were fixed and mounted directly and scored
visually for nuclear staining (or cellular distribution) using an
Olympus BX40 fluorescence microscope. For quantitation of nuclear
fluorescence of immunostained cells, slides were scanned with an
Optiscan confocal microscope at × 600 magnification, and several
fields from each slide were collected for quantitation. Within each
experiment, images from different slides were processed identically to
enable accurate quantitative comparison. Hundreds of individual cells
for each sample were quantified for nuclear fluorescence using the NIH image software as described previously (17).
Overexpression of Axin Induces Rapid Nuclear Export of Cellular
The nuclear export of In Vitro Nuclear Export of c-ABL Nuclear Export Is CRM1-dependent in the
Permeabilized Cell Assay--
To ensure that
CRM1-dependent nuclear export can be clearly detected in
this assay system, we tested the effect of leptomycin B on nuclear
export of c-ABL, a known shuttling protein that contains a
CRM1-responsive nuclear export signal (30, 35). In contrast to
Cellular and Ectopic
To confirm that CRM1 can affect In this study, we present evidence that During the preparation of this manuscript, Wiechens and Fagotto (37)
reported that labeled recombinant We studied human SW480 colon tumor cells that carry an inactivating and
truncating mutation in APC and consequently express high levels of
Previously, our laboratory (17) and others (18, 19) demonstrated
nuclear cytoplasmic shuttling of the In many tumor cells where the Given that
-Catenin is a mediator of the Wnt-signaling
pathway. In many cancers,
-catenin is stabilized and accumulates in
the nucleus where it associates with lymphoid-enhancing factor 1/
T-cell transcription factors to activate genes involved in cell
transformation. Previously, we showed that adenomatous polyposis coli
(APC) protein can regulate
-catenin localization by nuclear export.
In this study, we used in vitro transport assays to test
whether cellular
-catenin can exit the nucleus independent of APC
and the CRM1 export receptor. In digitonin-permeabilized SW480
(APCmut/mut) tumor cells, nuclear
-catenin decreased
>60% in export reactions in the absence of exogenous factors. Under
similar conditions, nuclear c-ABL was only exported after the addition
of cytosolic extract, and the export was blocked by the CRM1-specific
inhibitor, leptomycin B. The nuclear export of
-catenin was not
blocked by leptomycin B treatment, revealing a CRM1- and
APC-independent pathway. The export of
-catenin was sensitive to
lower temperatures and the removal of ATP, indicating an active
process. Ectopically expressed yellow fluorescent protein-
-catenin
also displayed CRM1-independent export. Conversely, the overexpression
of the CRM1 transporter moderately stimulated export of nuclear
-catenin, confirming that
-catenin exits the nucleus by at least
two distinct pathways. The shuttling ability of tumor cell
-catenin
has implications for its regulation and its role in transferring
signals between the nucleus and plasma membrane.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-Catenin is a multi-functional protein implicated in several
cellular processes including cell-cell adhesion and the transcriptional activation of genes (1-3).
-Catenin was first identified as a
component of the adherens junction complex, bound to the
intracellular domain of the transmembrane cell adhesion protein,
E-cadherin, helping to connect the cell surface with the internal actin
cytoskeleton (2, 3). The cadherin-bound form of
-catenin is anchored at the plasma membrane (4). Non-membrane-bound
-catenin, however, has a major function in transducing the Wnt signal from the cell surface to the nucleus (1, 2). In response to Wnt binding at the cell
surface,
-catenin is stabilized and actively translocates into the
nucleus where it binds to the lymphoid-enhancing factor 1 (LEF-1)1/T-cell transcription
factors. Nuclear
-catenin activates LEF-1/T-cell transcriptional
activity, thereby inducing the expression of genes involved in cellular
transformation and invasion, including c-myc (5),
cyclin D1 (6), and matrilysin (7).
-Catenin interacts with multiple proteins and is primarily regulated
by degradation. In the cytoplasm,
-catenin binds to the adenomatous
polyposis coli (APC) tumor suppressor, which initiates assembly of a
degradation complex comprising additional proteins, including Axin,
Conductin, and glycogen synthase kinase-3
(GSK-3
) (2, 8-10).
GSK-3
phosphorylates
-catenin at the N terminus, marking it for
ubiquitination and degradation by the proteasome complex (1, 9). Wnt
signaling inhibits this phosphorylation, leading to the stabilization
of
-catenin.
-Catenin is also stabilized in different cancers by
interference with the degradation pathway resulting from mutations in
its own gene (11, 12) or within the APC (1, 2, 8) and
Axin (13) genes. When stable
-catenin is
overexpressed, very often it accrues in the nucleus (3, 14, 15).
Therefore,
-catenin is a common focal point for Wnt growth factor
signaling and cancer, and its nuclear accumulation leads to the
oncogenic transformation of cells via
-catenin-dependent transcriptional activation (16).
-catenin from the nucleus to
the cytoplasm (17, 20). This activity was shown to stimulate
APC-dependent degradation of
-catenin (17, 20). There
are other pieces of evidence, however, that suggest an additional
nuclear export pathway for
-catenin that is independent to that
involving APC. Previously, Prieve and Waterman (21) reported indirect
evidence that a form of Xenopus
-catenin with a defective
APC-binding domain was able to be exported from the nucleus of
transfected lymphocytes after actinomycin D treatment. Also,
-catenin can enter the nucleus independently of soluble transport
factors, such as the importin receptors (22), raising the possibility
that movement in the reverse direction may also be true. More recently,
we compared the rates of
-catenin turnover in SW480 cells
transfected with either the degradation complex factors APC or Axin
(17). Unlike APC whose effect on
-catenin nuclear export and
degradation was blocked by leptomycin B, a specific inhibitor of the
CRM1 export receptor (23-27), Axin-induced
-catenin turnover was
not blocked by leptomycin B (17). How did the
-catenin move from
nucleus to cytoplasm to be degraded by Axin? By using an in
vitro nuclear transport assay, we examined the ability of
endogenous
-catenin to exit the nucleus of semi-permeabilized SW480
colon cancer cells. We show that unlike another oncogenic shuttling
protein, c-ABL, cellular
-catenin can exit the nucleus independent
of CRM1 and, therefore, represents a unique type of nuclear-
cytoplasmic shuttling protein. The ability of
-catenin to exit the
nucleus independent of APC suggests that nuclear shuttling is integral
to its regulation.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-Catenin, a monoclonal antibody C19220, which recognizes
C-terminal epitope, was from Transduction Laboratories; a rabbit
polyclonal antibody H-102, which recognizes C-terminal amino acids
680-781, and a goat polyclonal antibody C-18 were from Santa Cruz
Biotechnology; cABL, a rabbit polyclonal antibody K-12, which targets
amino acids 502-512 in central kinase domain, and a rabbit polyclonal
antibody C-19, which recognizes a C-terminal epitope, were from Santa
Cruz Biotechnology; and AP2, a rabbit polyclonal antibody C-18, which binds C terminus, was from Santa Cruz Biotechnology. The DNA
transfection of cells (usually 2 µg of DNA/2 ml of medium) was
performed with FuGene transfection reagent as directed by the supplier
(Roche Molecular Biochemicals) using cells at medium density seeded
onto coverslips.
-catenin
cDNA was excised from the vector p
-catenin/SKII+ (supplied by J. Behrens) as a SmaI-SalI fragment and cloned in
frame into the equivalent sites of a linker-modified eYFP-C1
(CLONTECH) expression vector. The resulting
plasmid, pYFP-
-catenin, was checked by restriction mapping and
sequencing, and the correct co-expression of both the YFP and
-catenin domains was confirmed in transfected cells by
immunofluorescent staining with three different
-catenin antibodies
(see above). The construction of the YFP-CRM1 vector was described
previously (28).
70 °C. Protein concentration was determined using the Bio-Rad
protein assay kit.
energy. +Energy indicates the addition of 1 mM
ATP, 0.5 mM GTP, 4 units/ml of creatine kinase, and 10 mM creatine phosphate, whereas
energy samples contained
10 mM sodium azide to deplete ATP. After the
transport reaction, cells were washed twice in PBS and fixed in 3%
formalin/PBS (Sigma). Transport reactions were performed either in a
30 °C incubator, or at 4° C, in which case cells were grown on
separate trays and all incubations and buffers were chilled on ice at
each step. For LMB treatments, high doses (~20 ng/ml) of the export
inhibitor were used throughout (confirmed to block CRM1-mediated export
in a GFP-based export assay (reviewed in Ref. 30)), and cells were
preincubated with LMB 30 min before digitonin treatment. All reagents,
except LMB, were obtained from Sigma or Roche Molecular Biochemicals
(23). Note that the addition of protease inhibitors helps to ensure that the disappearance of nuclear staining is more likely due to
nuclear export than nuclear degradation.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-Catenin Relocalization and
Degradation Independent of CRM1--
-Catenin accumulates in nuclei
of SW480 colon tumor cells, and recently, we showed that the
overexpression of APC enhanced the nuclear export and degradation of
-catenin in transfected SW480 cells (17). APC-dependent
relocalization of
-catenin requires the CRM1 export receptor (17,
18) and is blocked by the CRM1-specific inhibitor, leptomycin B (17,
20). Previously, we noted that the ectopic expression of Axin, a key
-catenin degradation factor, resulted in the disappearance of
-catenin from the nucleus and its cytoplasmic degradation, but that
this was not blocked by leptomycin B (17). Upon a more detailed
examination (see Fig. 1), we confirmed
that when
-catenin is released from an MG132-dependent
block to degradation, there is a partial but distinct shift from the
nucleus to cytoplasm wherein
-catenin is degraded by Axin complexes
(only in Axin-transfected cells). However, in contrast to APC, Axin
localization was not affected by leptomycin B but remained in the
cytoplasm or the perinuclear zone (see confocal images in Fig. 1). The
apparently fixed location of Axin suggests that
-catenin itself must
be capable of exiting the nucleus via a pathway insensitive to
leptomycin B treatment and, therefore, is independent of CRM1 and APC.

View larger version (60K):
[in a new window]
Fig. 1.
CRM1-independent relocalization of
-catenin in cells overexpressing Axin. SW480
cells were transfected with pFlag-Axin and stained after 48 h for
ectopic Axin (Flag Mab and fluorescein-conjugated secondary antibody)
and endogenous
-catenin (rabbit polyclonal H-102 and Texas Red
secondary antibody). Before processing, cells were treated for 12 h with 20 mM MG132 to block
-catenin degradation and
then stained directly, or after a 12-h chase in drug-free medium.
Confocal images show nuclear staining of
-catenin in Axin-expressing
cells before chase and the disappearance of
-catenin after the 12-h
chase. The proportion of transfected cells displaying nuclear
(N), nuclear and cytoplasmic (NC), or cytoplasmic
(C)
-catenin (gray bars), or a complete loss
of
-catenin (black bars) is shown graphed. The presence
of 6 ng/ml of LMB does not affect Axin localization or block
Axin-mediated degradation of
-catenin.
-Catenin Does Not Require CRM1
or Other Cytosolic Factors--
To test for CRM1-independent nuclear
export of
-catenin, we used a semi-permeabilized cell assay to
assess the ability of nuclear
-catenin to exit the nucleus of SW480
cells. In the absence of digitonin, immunofluorescence microscopy
detected
-catenin staining in both the nucleus and cytoplasm (Fig.
2). Treatment with 50 µg/ml digitonin,
which selectively permeabilizes the plasma membrane and not the nuclear
envelope (see under "Experimental Procedures") (32), followed by a
30-min incubation in transport buffer caused the near-complete
disappearance of endogenous
-catenin (Fig. 2). The same result was
obtained using two different antibodies (Mab C19220 and rabbit
polyclonal H-102). Quantitation of nuclear fluorescence from confocal
images revealed a 65% loss of nuclear
-catenin (see
graph in Fig. 2).

View larger version (91K):
[in a new window]
Fig. 2.
In vitro nuclear export of
-catenin is not blocked by leptomycin B. SW480
cells were permeabilized with 50 µg/ml digitonin (DIG),
and incubated for 30 min (at 30 °C) in transport buffer containing
an energy-regenerating system (see under "Experimental Procedures")
with or without the addition of 50 µg of cytoplasmic extract
(CE) or 20 ng/ml of leptomycin B (LMB). Cellular
-catenin was detected with the monoclonal antibody C19220
(Transduction Laboratories), and confocal microscopy showed that
-catenin staining virtually disappeared after digitonin treatment,
independent of extract addition. Quantification of nuclear fluorescence
revealed a 65% decrease in nuclear
-catenin levels, whereas the AP2
transcription factor did not exit the nucleus. Results shown are the
mean ± S.E. of at least two independent experiments.
n, number of cells analyzed.
-catenin was only modestly enhanced (~10%)
by the addition of cytoplasmic (Fig. 2) or nuclear extract (data not
shown). More important, the addition of high doses of leptomycin B did
not significantly block in vitro export of the endogenous
-catenin (Fig. 2). The small effect of LMB we observed (a 5% block
to export) may reflect the low proportion of endogenous APC-bound
-catenin in these cells (33, 34). Our results indicate that the
majority of
-catenin can exit the nucleus in the absence of CRM1 or
other exogenous soluble factors. This experiment was performed many
times with different preparations of digitonin and always produced the
same result. Under comparable conditions, no decrease in nuclear
staining was observed after the immunostaining of the AP2 transcription
factor (Fig. 2). In fact, digitonin treatment had the opposite effect
and induced cytoplasmic AP2 to enter but not exit the nucleus. The
enhanced nuclear AP2 levels in digitonin-permeabilized cells may result
from the depletion of a factor that controls AP2 nuclear import.
-Catenin Is Energy- and
Temperature-dependent--
Previously, it was reported
that the nuclear import of recombinant
-catenin can occur
independent of the importin receptors, but that the import was
sensitive to changes in temperature and energy (22). We tested these
parameters for their effect on
-catenin nuclear export in SW480
cells (Fig. 3). After digitonin treatment, a 30-min incubation at 4 °C resulted in the disappearance of soluble cytoplasmic
-catenin from cells, leaving a strong concentration of staining in the nucleus and at the plasma membrane (see confocal images in Fig. 3). The quantitation of nuclear
fluorescence in hundreds of cells showed that nuclear export was
completely blocked at the lower temperature, independent of available
ATP/GTP (Fig. 3, lower panel). By contrast, at the higher
temperature (30 °C), most
-catenin nuclear staining disappeared
after digitonin treatment in the presence of an energy-regenerating
system. Removal of ATP at this temperature partially blocked the
export, decreasing nuclear staining by 40%. Thus,
-catenin nuclear
export appears to be an active process. These results also confirm that
the presence of digitonin does not interfere with the cell-staining
method used in this assay.

View larger version (79K):
[in a new window]
Fig. 3.
-Catenin nuclear export is
sensitive to temperature and energy. SW480 cells were left
untreated or permeabilized with digitonin (DIG) and then
incubated for 30 min at different temperatures in the presence or
absence of an added energy supply (for details see under
"Experimental Procedures"). Cells were immunostained for
-catenin, and confocal images were quantified for
-catenin
nuclear fluorescence. All samples were processed identically within
each experiment. At 4 °C,
-catenin export was blocked. At
30 °C, export was partially blocked in the absence of added ATP/GTP,
indicating that
-catenin nuclear export is an active process.
-catenin, nuclear c-ABL levels did not decrease in digitonin-treated SW480 cells incubated in transport buffer alone for 30 min at 30 °C
(Fig. 4). Nuclear export of c-ABL
required the addition of cytoplasmic extract, and the extract-induced
export was inhibited either by lower temperatures or by leptomycin B
treatment (Fig. 4). Similar results were obtained with two different
c-ABL antibodies (C19 and K12, see Fig. 4). These results demonstrate
that c-ABL nuclear export requires exogenous soluble factors,
particularly CRM1, and highlight the unique nature of the
-catenin
export pathway.

View larger version (68K):
[in a new window]
Fig. 4.
CRM1-dependent nuclear export of
c-ABL. SW480 cells were analyzed for nuclear export of c-ABL under
different conditions. As shown, nuclear staining was very strong in
digitonin-treated cells in the absence of the cytoplasmic extract
(CE). In contrast to
-catenin, c-ABL nuclear export
required an addition of 50 µg/ml cytoplasmic extract and was blocked
by the addition of 20 ng/ml of LMB, suggesting that efficient export
requires CRM1. Nuclear export was also blocked when the transport
reactions were performed on ice (see quantification in
graphs). Very similar results were obtained using two
different c-ABL polyclonal antibodies, C19 (which recognizes a
C-terminal epitope) and K12 (which recognizes the central kinase
domain), from Santa Cruz Biotechnology. The reduced effect of LMB in
cells stained with C19 antibody may reflect a partial masking of c-ABL
C-terminal epitopes (e.g. by binding of F-actin) after the
addition of cytosolic extract.
-Catenin Exit the Nucleus by Two Distinct
Pathways--
We next showed that ectopically expressed
-catenin
also displays rapid and CRM1-independent nuclear export. In
vitro nuclear export activities of YFP or YFP-
-catenin and
YFP-CRM1 fusion proteins were compared in transfected SW480 cells. As
shown in Fig. 5A, the
-catenin fusion protein exited the nucleus of digitonin-treated cells more efficiently than did the CRM1 export receptor and almost as
easily as YFP alone. Similar results were obtained in NIH 3T3 fibroblasts (data not shown). This confirms that ectopic
YFP-
-catenin, which in transfected SW480 cells shows a comparable
nuclear-cytoplasmic distribution to endogenous
-catenin, displayed a
similar ability to exit the nucleus rapidly. Moreover, the nuclear
export of YFP-
-catenin was also inhibited by a small but consistent
margin in the presence of leptomycin B (Fig. 5B), suggesting
that in SW480 cells CRM1 makes only a modest contribution to
-catenin nuclear transport.

View larger version (28K):
[in a new window]
Fig. 5.
Evidence for two distinct
-catenin nuclear export pathways in SW480
cells. A, CRM1-independent export of ectopic
-catenin. SW480 cells were transfected with pEYFP-C1
(YFP) or YFP-
-catenin and YFP-CRM1 fusion vectors
permeabilized with 0, 30, or 50 µg/ml digitonin and then incubated in
transport buffer (+energy) for 30 min at 30 °C. After 48 h,
cells were fixed, and the number of cells with nuclear fluorescence
visible by fluorescence microscopy were scored (total cells counted are
shown in brackets). Similar to cellular
-catenin, the
ectopic YFP-
-catenin very efficiently exits the nucleus in the
absence of added soluble factors. B, SW480 cells transfected
with YFP-
-catenin or p19ARF-GFP (a protein usually
restricted to the nucleus/nucleolus) were treated with 50 µg/ml
digitonin and examined for export. YFP-
-catenin nuclear export was
partially blocked (10% more cells retained nuclear staining) in the
presence of LMB. p19ARF-GFP was not exported in
permeabilized cells. The results from a typical experiment are shown
with similar results obtained in at least two experiments.
C, effect of CRM1 overexpression on nuclear
-catenin.
SW480 cells were transfected with YFP or the YFP-CRM1 fusion, and after
48 h, cells were stained for
-catenin localization. As shown in
the confocal images and graphs, transient expression of the export
receptor had a small but specific effect on cellular
-catenin,
causing its movement out of the nucleus.
-catenin localization in SW480
cells, we overexpressed a YFP fusion of the CRM1 export receptor and
examined its effect on endogenous
-catenin (Fig. 5C).
Nuclear
-catenin staining was significantly reduced in up to 25% of
YFP-CRM1-transfected cells compared with 5% of cells transfected with
YFP alone (Fig. 5C). Although it is possible that CRM1
overexpression is boosting the export of cellular APC-
-catenin
complexes, we cannot exclude the presence of an additional
CRM1-dependent export pathway. When considered together,
these results provide strong evidence that
-catenin can exit the
nucleus by at least two distinct pathways, one involving CRM1 and APC
and the other independent of the CRM1 export receptor.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-catenin can
independently shuttle between the nucleus and cytoplasm. Previously, it
was shown that
-catenin can enter the nucleus independent of the
importin receptors and the Ran-GTPase (22, 36). Here, we used a
digitonin-permeabilized cell assay to show that cellular and
ectopically expressed
-catenin can exit the nucleus by a rapid and
active process, which does not require the CRM1 export receptor. This
discovery reveals that human
-catenin can exit the nucleus of tumor
cells by a pathway distinct from that recently shown to require an
association with the APC tumor suppressor (17-20). Thus, in contrast
to previous claims (19),
-catenin is not trapped in the nucleus of
tumor cells that express APC mutations.
-catenin is also exported
independent of CRM1 following microinjection into the nuclei of
Xenopus laevis oocytes. The two studies, which focus on
different forms of
-catenin in different species, together demonstrate conservation in the nuclear transport of
-catenin and
challenge the notion that monomeric
-catenin transfers a unidirectional signal to the nucleus after Wnt binding at the plasma
membrane (1). Instead, the shuttling of
-catenin suggests a more
intricate regulatory circuit initiated by Wnt signaling and present in
cancer cells, with the possibility of some type of feedback control.
-catenin in the nucleus and cytoplasm. The ability of endogenous
-catenin to quickly exit the nucleus of SW480 cells without the
addition of exogenous transport factors is unusual, as illustrated by
the fact that the nuclear export of another oncogenic protein, c-ABL,
was strictly dependent on the addition of CRM1-containing cytosolic
extract in this system (Fig. 4). The recent study of Wiechens and
Fagotto (37) reveals that the nuclear export of recombinant
Xenopus
-catenin can occur independent of CRM1 and of
Ran-GTP and involves N-terminal and C-terminal sequences that bear no
resemblance to known nuclear transport motifs. Interestingly, complete
nuclear export of recombinant
-catenin in the microinjected
Xenopus eggs required up to 6 h (37), whereas the
near-complete nuclear export of cellular
-catenin that we observed
occurred within 30 min of digitonin treatment of human cells (Fig.
2). The slower transport kinetics observed in injected frog
nuclei may reflect saturation of the system, as it was proposed that
some "unidentified" factor required for
-catenin export was
present in limiting amounts (37).
-catenin-binding protein, APC.
Based on evidence from cell transfection experiments, it was proposed
that APC (bound to the CRM1 export receptor via its nuclear export
signals) can carry
-catenin from the nucleus to the cytoplasm (17,
19, 20). This pathway is likely to be more important in cells where the
-catenin degradation pathway is intact. In such cells, there is
little uncomplexed
-catenin, and its localization will be determined
primarily by its binding partners. For instance, when
-catenin is
bound to E-cadherin, it is anchored at the plasma membrane (4).
LEF-1-bound
-catenin is anchored in the nucleus (reviewed in Ref. 38
and data not shown), whereas APC-bound
-catenin can potentially move
between the nucleus and cytoplasm. Because the main N-terminal nuclear export signals of APC are well removed from the
-catenin binding sites (17, 18), it is reasonable to propose that APC-
-catenin complexes preassemble in the nucleus (17, 20) and then translocate to
the cytoplasm where they associate with other factors (e.g. Axin and GSK-3
) required for
-catenin turnover.
-catenin degradation pathway is
impaired by mutations in the APC,
-catenin, or Axin genes,
-catenin is quite stable and can accumulate to very high levels in
both the nucleus and cytoplasm (3, 13, 39). In SW480 cells, which
express mutated APC, endogenous
-catenin is expressed well in excess
of APC and, to a large extent, is present in a free form uncomplexed
with other proteins (33, 34). The identification of a CRM1-independent
export pathway (as described in this study and in Ref. 37) suggests
that APC would have little impact, unless overexpressed, on the
transport or localization of
-catenin in these cells. Therefore, we
speculate that APC-dependent export of
-catenin is
dominant in normal cells, whereas the high levels of free
-catenin
in tumor cells exit the nucleus independent of APC and the CRM1 exporter.
-catenin can efficiently exit the nucleus, why is it so
often detected in the nucleus? When
-catenin was overexpressed in
Xenopus cells, it did not accumulate well in the nucleus
(37). In mammalian cells, however, many studies have reported nuclear staining of
-catenin when it is stabilized (3, 15) or overexpressed (14, 15). Indeed, the transient expression of a YFP-
-catenin fusion
displayed strong nuclear and cytoplasmic staining in different cell
lines (data not shown). The nuclear accumulation of overexpressed
-catenin may reflect a combination of nuclear retention and possibly a higher rate of nuclear import relative to export. This balance would
change in cells where the ratio of APC to
-catenin molecules is much
higher and where APC contributes to the export/degradation of
-catenin.
-Catenin behaves not unlike nuclear transporter molecules in its
ability to freely translocate across the nuclear membrane in either
direction. Whereas this movement seems to be independent of the
importin, CRM1, and Ran nuclear transport factors, the data from
competition experiments suggest that another factor may be required for
the nuclear export of
-catenin (37). There are some structural
similarities between repeat sequences in
-catenin and the
importin-
nuclear import receptor (40), and interestingly, importin-
was also found to exit the nucleus independent of the Ran-GTPase (41). Although there is no clear evidence that
-catenin can act as a transporter of other molecules, its ability to rapidly move around the cell and associate with different partners may be
integral to its role as a signaling intermediate in the Wnt pathway
(1-3). It is possible that GSK-3
-mediated phosphorylation of
-catenin (targets
-catenin for ubiquitination) is a cytoplasmic event, and that nuclear shuttling allows for the rapid modification of
both nuclear and cytoplasmic
-catenin in the cell. Alternatively,
-catenin may be modified in the nucleus, thus altering its activity or ability to associate with specific binding partners in the cytoplasm. The constant cycling of
-catenin in tumor cells means that it will seek out and bind any partners (e.g.
E-cadherin, LEF-1, retinoic acid receptor (see Ref. 42)) regardless of
their location within the cell. It will now prove important to define precisely how the dynamic intracellular trafficking of
-catenin impacts on its regulation and function.
| |
ACKNOWLEDGEMENTS |
|---|
We thank J. Behrens and W. Birchmeier for
supplying the full-length
-catenin cDNA, Trevor Dale for
supplying pFlag-Axin, and Helen Rizos for providing
p19ARF-GFP.
| |
FOOTNOTES |
|---|
* This work was supported by grants from the New South Wales Cancer Council and the National Health and Medical Research Council (NHMRC) (to B. R. H.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Research fellow of NH and MRC.
¶ To whom correspondence should be addressed: Westmead Inst. for Cancer Research (WICR), Westmead Millennium Inst., Darcy Rd., P. O. Box 412, Westmead, NSW 2145, Australia. Tel.: 6-2-9845-9057; Fax: 61-2-9845-9102; E-mail: beric_henderson@wmi.usyd.edu.au.
Published, JBC Papers in Press, May 3, 2001, DOI 10.1074/jbc.M102656200
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
LEF, lymphoid-enhancing factor;
APC, adenomatous polyposis coli;
GSK-3
, glycogen synthase kinase 3
;
CRM1, chromosome region maintenance 1;
YFP, yellow fluorescent protein;
GFP, green fluorescent protein;
PBS, phosphate-buffered saline;
LMB, leptomycin B;
AP2, activating protein
2.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Polakis, P. (2000) Genes Dev. 14, 1837-1851 |
| 2. | Peifer, M., and Polakis, P. (2000) Science 287, 1606-1609 |
| 3. | Morin, P. J. (1999) Bioessays 21, 1021-1030 |
| 4. | Orsulic, S., Huber, O., Aberle, H., Arnold, S., and Kemler, R. (1999) J. Cell Sci. 112, 1237-1245 |
| 5. | He, T. C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., DaCosta, L. T., Morin, P. J., Vogelstein, B., and Kinzler, K. W. (1998) Science 281, 1509-1512 |
| 6. | Tetsu, O., and McCormack, F. (1999) Nature 398, 422-426 |
| 7. | Crawford, H. C., Fingleton, B. M., Rudolph-Owen, L. A., Heppner Goss, K. J., Rubinfeld, B., Polakis, P., and Matrisian, L. M. (1999) Oncogene 18, 2883-2891 |
| 8. | Kinzler, K. W., and Vogelstein, B. (1996) Cell 87, 159-170 |
| 9. | van Es, J. H., Giles, R. H., and Clevers, H. C. (2001) Exp. Cell Res. 264, 126-134 |
| 10. | Hart, M. J., de los Santos, R., Albert, I. N., Rubinfeld, B., and Polakis, P. (1998) Curr. Biol. 8, 573-581 |
| 11. | Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., and Kinzler, K. W. (1997) Science 275, 1787-1790 |
| 12. | Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., and Polakis, P. (1997) Science 275, 1790-1792 |
| 13. | Satoh, S., Daigo, Y., Furukawa, Y., Kato, T., Miwa, N., Nishiwaki, T., Kawasoe, T., Ishiguro, H., Fujita, M., Tokino, T., et al.. (2000) Nat. Genet. 24, 245-250 |
| 14. | Simcha, I., Shtutman, M., Salomon, D., Zhurinsky, J., Sadot, E., Geiger, B., and Ben-Ze'ev, A. (1998) J. Cell Biol. 141, 1433-1448 |
| 15. | Harada, N., Tamai, Y., Ishikawa, T-O, Sauer, B., Takaku, K., Oshima, M., and Taketo, M. M. (1999) EMBO J. 18, 5931-5942 |
| 16. | Aoki, M., Hecht, A., Kruse, U., Kemler, R., and Vogt, P. K. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 139-144 |
| 17. | Henderson, B. R. (2000) Nat. Cell Biol. 2, 653-660 |
| 18. | Neufeld, K. L., Nix, D. A., Bogerd, H., Kang, Y., Beckerle, M. C., Cullen, B. R., and White, R. L. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 12085-12090 |
| 19. | Rosin-Arbesfeld, R., Townsley, F., and Bienz, M. (2000) Nature 406, 1009-1012 |
| 20. | Neufeld, K. L., Zhang, F., Cullen, B., and White, R. L. (2000) EMBO Rep. 1, 519-523 |
| 21. | Prieve, M. G., and Waterman, M. L. (1999) Mol. Cell. Biol. 19, 4503-4515 |
| 22. | Fagotto, F., Gluck, U., and Gumbiner, B. M. (1997) Curr. Biol. 8, 181-190 |
| 23. | Kudo, N., Wolff, B., Sekimoto, T., Schreiner, E. P., Yoneda, Y., Yanagida, M., Horinouchi, S., and Yoshida, M. (1998) Exp. Cell Res. 242, 540-547 |
| 24. | Ossareh-Nazari, B., Bachelerie, F., and Dargemont, C. (1997) Science 278, 141-144 |
| 25. | Fornerod, M., Ohno, M., Yoshida, M., and Mattaj, I. W. (1997) Cell 90, 1051-1060 |
| 26. | Stade, K., Ford, C. S., Guthrie, C., and Weis, K. (1997) Cell 90, 1041-1050 |
| 27. | Fukuda, M., Ansano, S., Nakamura, T., Adachi, M., Yoshida, M., Yanagida, M., and Nishida, E. (1997) Nature 390, 308-311 |
| 28. | Rodriguez, J. A., and Henderson, B. R. (2000) J. Biol. Chem. 275, 38589-38596 |
| 29. | Gorlich, D., Prehn, S., Laskey, R. A., and Hartmann, E. (1994) Cell 79, 767-778 |
| 30. | Henderson, B. R., and Eleftheriou, A. (2000) Exp. Cell Res. 256, 213-224 |
| 31. | Nakielny, S., and Dreyfuss, G. (1997) Curr. Biol. 8, 89-95 |
| 32. | Adam, S. A., Marr, R. S., and Gerace, L. (1990) J. Cell Biol. 11, 807-816 |
| 33. | Munemitsu, S., Albert, I., Souza, B., Rubinfeld, B., and Polakis, P. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3046-3050 |
| 34. | Porfiri, E., Rubinfeld, B., Albert, I., Hovanes, K., Waterman, M., and Polakis, P. (1997) Oncogene 15, 2833-2839 |
| 35. | Taagepera, S., McDonald, D., Loeb, J. E., Whitaker, L. L., McElroy, A. K., Wang, J. Y. J., and Hope, T. J. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7457-7462 |
| 36. | Yokoya, F., Imamoto, N., Tachibana, T., and Yoneda, Y. (1999) Mol. Biol. Cell 10, 1119-1131 |
| 37. | Wiechens, N., and Fagotto, F. (2001) Curr. Biol. 11, 18-27 |
| 38. | Behrens, J., von Kries, J. P., Kuhl, M., Bruhn, L., Wedlich, D., Grosschedl, R., and Birchmeier, W. (1996) Nature 382, 638-642 |
| 39. | Kongkanuntn, R., Bubb, V. J., Sansom, O. J., Wyllie, A. H., Harrison, D. J., and Clarke, A. (1999) Oncogene 18, 7219-7225 |
| 40. | Lee, S. J., Imamoto, N., Sakai, H., Nakagawa, A., Kose, S., Koike, M., Yamamoto, M., Kumasaka, T., Yoneda, Y., and Tsukihara, T. (2000) J. Mol. Biol. 302, 251-264 |
| 41. | Kose, S., Imamoto, N., Tachibana, T., Yoshida, M., and Yoneda, Y. (1999) J. Biol. Chem. 274, 3946-3952 |
| 42. | Easwaran, V., Pishvaian, M., Salimuddin, and Byers, S. (1999) Curr. Biol. 9, 1415-1418 |
This article has been cited by other articles:
![]() |
F.-Q. Li, A. Mofunanya, K. Harris, and K.-I. Takemaru Chibby cooperates with 14-3-3 to regulate {beta}-catenin subcellular distribution and signaling activity J. Cell Biol., June 30, 2008; 181(7): 1141 - 1154. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sharma and B. R. Henderson IQ-domain GTPase-activating Protein 1 Regulates beta-Catenin at Membrane Ruffles and Its Role in Macropinocytosis of N-cadherin and Adenomatous Polyposis Coli J. Biol. Chem., March 16, 2007; 282(11): 8545 - 8556. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Junaid, M. C. Moon, G. E. J. Harding, and P. Zahradka Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1 Am J Physiol Cell Physiol, February 1, 2007; 292(2): C919 - C926. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Thyssen, T.-H. Li, L. Lehmann, M. Zhuo, M. Sharma, and Z. Sun LZTS2 Is a Novel {beta}-Catenin-Interacting Protein and Regulates the Nuclear Export of {beta}-Catenin Mol. Cell. Biol., December 1, 2006; 26(23): 8857 - 8867. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sharma, L. Leung, M. Brocardo, J. Henderson, C. Flegg, and B. R. Henderson Membrane Localization of Adenomatous Polyposis Coli Protein at Cellular Protrusions: TARGETING SEQUENCES AND REGULATION BY beta-CATENIN J. Biol. Chem., June 23, 2006; 281(25): 17140 - 17149. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Krieghoff, J. Behrens, and B. Mayr Nucleo-cytoplasmic distribution of {beta}-catenin is regulated by retention. J. Cell Sci., April 1, 2006; 119(Pt 7): 1453 - 1463. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xiong and Y. Kotake No exit strategy? No problem: APC inhibits beta-catenin inside the nucleus. Genes & Dev., March 15, 2006; 20(6): 637 - 642. [Full Text] [PDF] |
||||
![]() |
J. Hendriksen, F. Fagotto, H. van der Velde, M. van Schie, J. Noordermeer, and M. Fornerod RanBP3 enhances nuclear export of active {beta}-catenin independently of CRM1 J. Cell Biol., December 5, 2005; 171(5): 785 - 797. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Cong and H. Varmus Nuclear-cytoplasmic shuttling of Axin regulates subcellular localization of {beta}-catenin PNAS, March 2, 2004; 101(9): 2882 - 2887. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Le Gallic, L. Virgilio, P. Cohen, B. Biteau, and G. Mavrothalassitis ERF Nuclear Shuttling, a Continuous Monitor of Erk Activity That Links It to Cell Cycle Progression Mol. Cell. Biol., February 1, 2004; 24(3): 1206 - 1218. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Li and R. Iyengar Calpain as an effector of the Gq signaling pathway for inhibition of Wnt/beta -catenin-regulated cell proliferation PNAS, October 1, 2002; 99(20): 13254 - 13259. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Lee, K. A. D'Amour, and J. Papkoff A yeast model system for functional analysis of {beta}-catenin signaling J. Cell Biol., September 16, 2002; 158(6): 1067 - 1078. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Henderson, M. Galea, S. Schuechner, and L. Leung Lymphoid Enhancer Factor-1 Blocks Adenomatous Polyposis Coli-mediated Nuclear Export and Degradation of beta -Catenin. REGULATION BY HISTONE DEACETYLASE 1 J. Biol. Chem., June 28, 2002; 277(27): 24258 - 24264. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Mulholland, H. Cheng, K. Reid, P. S. Rennie, and C. C. Nelson The Androgen Receptor Can Promote beta -Catenin Nuclear |